• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Provident Financial Services

Provident Financial Services

Fidelity Advisor Asset Manager® 50% T FFTMX 2 Star

Last Price$17.24Day Change (%)0.06%
Open Price$17.24Day Change ($)0.01
Day Range17.24–17.2452-Week Range15.37–17.24

As of Mon 02/20/2017 | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma

    Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma

  2. Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma

    Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma

  3. Aeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium

    Aeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium

  4. Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

    Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

  5. UPDATE: One financial adviser's wish list for financial and tax reform

    UPDATE: One financial adviser's wish list for financial and tax reform

  6. PACCAR Achieves Very Good Annual Revenues and Profits

    PACCAR Achieves Very Good Annual Revenues and Profits

  7. ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency

    ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency

  8. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

    IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

  9. BIOCORP to Present Its Innovations at 20th Pharmapack Exhibition, on 1st-2nd February 2017 in Paris

    BIOCORP to Present Its Innovations at 20th Pharmapack Exhibition, on 1st-2nd February 2017 in Paris

  10. NAPFA’s CFP-Only Stand: A Step in the Wrong Direction

    A curious move, at a curious time, for purportedly, a curious reason, that is also a slap in the face to CPAs with the PFS credential.

123

©2017 Morningstar Advisor. All right reserved.